Zoledronate

BreastfeedingGeriatricPediatric
  • TRADE NAMES: Aclasta (Novartis); Reclast (Novartis); Zometa (Novartis)
  • INDICATIONS: Hypercalcemia of malignancy, Paget's disease, osteoporosis
  • SYNONYM: zoledronic acid
  • CLASS: Bisphosphonate
  • HALF-LIFE: 7 days
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

Aminoglycosides, Bisphosphonates, Loop diuretics, Nephrotoxics

PREGNANCY CATEGORY: D

Our database has 103 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN
HAIR
MUCOSAL
CARDIOVASCULAR
CENTRAL NERVOUS SYSTEM
NEUROMUSCULAR/SKELETAL
GASTROINTESTINAL/HEPATIC
RESPIRATORY
ENDOCRINE/METABOLIC
GENITOURINARY
RENAL
HEMATOLOGIC
OCULAR
LOCAL
OTHER


Visit Informa

Click on the DRUG REVIEW ARTICLE tab (above) to see a review of zoledronate in the Taylor & Francis journal Expert Opinion on Drug Safety. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)

Page last updated 10/23/2017

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric